Steris (NYSE:STE)‘s stock had its “market perform” rating reiterated by research analysts at Raymond James Financial in a research note issued to investors on Wednesday, January 3rd, Marketbeat reports. They currently have a $100.00 price target on the medical equipment provider’s stock. Raymond James Financial’s price objective would indicate a potential upside of 9.09% from the stock’s current price.
Several other analysts also recently commented on STE. Zacks Investment Research raised shares of Steris from a “hold” rating to a “buy” rating and set a $101.00 target price for the company in a research report on Monday, October 9th. KeyCorp reissued a “buy” rating and issued a $91.00 target price on shares of Steris in a research report on Tuesday, October 17th. Finally, TD Securities upped their price objective on shares of Steris from C$14.00 to C$16.00 and gave the stock a “buy” rating in a report on Thursday, November 9th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $79.50.
Shares of Steris (STE) opened at $91.67 on Wednesday. Steris has a fifty-two week low of $65.26 and a fifty-two week high of $93.39. The company has a quick ratio of 2.18, a current ratio of 2.80 and a debt-to-equity ratio of 0.48. The company has a market cap of $7,691.29, a P/E ratio of 54.57 and a beta of 1.27.
Steris (NYSE:STE) last released its quarterly earnings results on Wednesday, November 1st. The medical equipment provider reported $0.94 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $0.95 by ($0.01). Steris had a net margin of 5.59% and a return on equity of 11.49%. The firm had revenue of $634.20 million for the quarter, compared to analyst estimates of $629.02 million. During the same quarter in the prior year, the firm earned $0.89 EPS. The firm’s revenue was down 1.9% compared to the same quarter last year. analysts predict that Steris will post 4.06 earnings per share for the current fiscal year.
In related news, VP John Adam Zangerle sold 3,650 shares of the stock in a transaction dated Tuesday, November 14th. The shares were sold at an average price of $88.00, for a total transaction of $321,200.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Michael J. Tokich sold 11,000 shares of the stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $92.00, for a total transaction of $1,012,000.00. Following the sale, the insider now directly owns 58,588 shares in the company, valued at approximately $5,390,096. The disclosure for this sale can be found here. Corporate insiders own 2.55% of the company’s stock.
A number of large investors have recently modified their holdings of STE. Janus Henderson Group PLC boosted its stake in shares of Steris by 1,972.4% in the 2nd quarter. Janus Henderson Group PLC now owns 7,679,507 shares of the medical equipment provider’s stock valued at $625,880,000 after purchasing an additional 7,308,950 shares during the last quarter. BlackRock Inc. boosted its stake in shares of Steris by 33.4% in the 2nd quarter. BlackRock Inc. now owns 7,032,984 shares of the medical equipment provider’s stock valued at $573,188,000 after purchasing an additional 1,760,879 shares during the last quarter. Koch Industries Inc. bought a new position in shares of Steris in the 2nd quarter valued at about $1,089,000. FMR LLC boosted its stake in shares of Steris by 33.1% in the 2nd quarter. FMR LLC now owns 3,454,533 shares of the medical equipment provider’s stock valued at $281,544,000 after purchasing an additional 859,228 shares during the last quarter. Finally, State Street Corp boosted its stake in shares of Steris by 53.2% in the 2nd quarter. State Street Corp now owns 2,336,074 shares of the medical equipment provider’s stock valued at $190,392,000 after purchasing an additional 811,622 shares during the last quarter. 89.40% of the stock is currently owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Steris (NYSE:STE) Given “Market Perform” Rating at Raymond James Financial” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally copied and republished in violation of US & international copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/13/raymond-james-financial-reaffirms-market-perform-rating-for-steris-ste.html.
STERIS plc provides infection prevention and other procedural products and services. The Company operates through four segments: Healthcare Products, which offers infection prevention and procedural solutions for healthcare providers, including capital equipment and related maintenance, and installation services, as well as consumables; Healthcare Specialty Services, which provides a range of specialty services for healthcare providers, including hospital sterilization services, instrument and scope repairs, and linen management; Life Sciences, which offers capital equipment and consumable products, and equipment maintenance and specialty services for pharmaceutical manufacturers and research facilities, and Applied Sterilization Technologies, which offers contract sterilization and laboratory services for medical device and pharmaceutical customers and others.
Receive News & Ratings for Steris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Steris and related companies with MarketBeat.com's FREE daily email newsletter.